$BKLLF / $CODE As previously announced, the Company is not making any express or implied claims that HCQ or CQ has any effect in the prevention or treatment of COVID-19 at this time. Developing a transdermal or oral mucosal delivery of these drugs should lead to the lessening of the dosage required and the common side effects felt by current users of these drugs for their on-label treatment for lupus, rheumatoid arthritis and malaria.

1 https://pubmed.ncbi.nlm.nih.gov/32359203/

2 https://www.cnbc.com/2020/04/15/coronavirus-u...speed.html

https://www.otcmarkets.com/stock/BKLLF/news/C...?id=261673

$WRHLF